Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney

Molecular Pharmacology

Volumn 67, Issue 2, 2005, Pages 453-459

  Damaraju, Vijaya L ^a,b   Hamilton, Katherine F ^a,b   Seth Smith, Michelle L ^a,b   Cass, Carol E ^a,b   Sawyer, Michael B ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AMINOPTERIN; FOLATE RECEPTOR; FOLIC ACID ANTAGONIST; FOLIC ACID DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL; PLEVITREXED; RALTITREXED;

ARTICLE; BINDING SITE; BRUSH BORDER VESICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG RECEPTOR BINDING; ENZYME DEGRADATION; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MEMBRANE VESICLE; OSMOLARITY; PH; PRIORITY JOURNAL;

CELL MEMBRANE; CYTOPLASMIC VESICLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY TUBULES, PROXIMAL; MICROVILLI; PROTEIN BINDING;

EID: 13444269675     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.004978     Document Type: Article

References (27)

1. Agbanyo FR, Cass CE, and Paterson AR (1988) External location of sites on pig erythrocyte membranes that bind nitrobenzylthioinosine. Mol Pharmacol 33:332-337.
2. Azarnoff DL, Wan SH, and Huffman DH (1974) Pharmacokinetics of methotrexate. Clin Pharmacol Ther 16:884-885.
3. 14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 42:71-76.
4. Booth AG and Kenny AJ (1974) A rapid method for the preparation of microvilli from rabbit kidney. Biochem J 142:575-581.
5. Calvert AH, Bondy PK, and Harrap KR (1977) Some observations on the human pharmacology of methotrexate. Cancer Treat Rep 61:1647-1656.
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, and Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16:2943-2952.
8. Corrocher R, Abramson RG, King VF, Schreiber C, Dikman S, and Waxman S (1985) Differential binding of folates by rat renal cortex brush border and basolateral membrane preparations. Proc Soc Exp Biol Med 178:73-84.
9. de Koning HP and Jarvis SM (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop 80:245-250.
10. Glode LM, Pitman SW, Ensminger WD, Rosowsky A, Papathanasopoulos N, and Frei E 3rd (1979) A phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. Cancer Res 39:3707-3714.
11. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, et al. (2001) Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 19:1476-1484.
12. Goresky C, Watanabe H, and Johns D (1963) The renal excretion of folic acid. J Clin Investis 42:1841-1849.
13. Huffman DH, Wan SH, Azarnoff DL, and Halprin KM (1972) Half-life of methotrexate: new evidence. Arch Dermatol 105:761-762.
14. Jackman AL, Kimbell R, Brown M, Brunton L, Harrap KR, Wardleworth JM, and Boyle FT (1994) The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 370:185-188.
15. McMartin KE, Morshed KM, Hazen-Martin DJ, and Sens DA (1992) Folate transport and binding by cultured human proximal tubule cells. Am J Physiol 263:F841-F848.
16. McMartin KE, Virayotha V, and Tephly TR (1981) High-pressure liquid chromatography separation and determination of rat liver folates. Arch Biochem Biophys 209:127-136.
17. Monjanel S, Rigault JP, Cano JP, Carcassonne Y, and Favre R (1979) High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 3:189-196.
18. Morshed KM, Ross DM, and McMartin KE (1997) Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J Nutr 127:1137-1147.
19. Pui CH and Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339:605-615.
20. Rinaldi DA, Kuhn JG, Burns HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, et al. (1999) A phase I evaluation of multi-targeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380.
21. Ross JF, Chaudhuri PK, and Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432-2443.
22. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, and Iglesias J (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194.
23. Sawyer M, Ratain MJ, Janisch L, Smith R, Fleming G, Schilsky RL, Shulman K, Vogelzang NJ, DeMario M, and Douglass E (2000) A phase I study of Zd 9331 (Zd) administered orally for up to 28 days every 6 weeks, in Proceedings of the American Society of Clinical Oncology Thirty-Sixth Annual Meeting (Perry M ed); 2000 May 20-23; New Orleans, LA; pp 236a, Lippincott Williams & Wilkins, Baltimore.
24. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, and Fleming GF (2003) Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol 21:1859-1865.
25. Selhub J and Rosenberg IH (1978) Demonstration of high-affinity folate binding activity associated with the brush border membranes of rat kidney. Proc Natl Acad Sci USA 75:3090-3093.
26. Sessa C, Zucchetti M, Ginier M, Willems Y, D'Incalci M, and Cavalli F (1988) Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717. Eur J Cancer Clin Oncol 24:769-775.
27. Verma RS, Gullapalli S, and Antony AC (1992) Evidence that the hydrophobicity of isolated, in situ and de novo-synthesized native human placental folate receptors is a function of glycosyl-phosphatidylinositol anchoring to membranes. J Biol Chem 267:4119-4127.